KR950704494A - Vaccine against varicella-zoster virus (VZV) (VACCINES AGAINST VARICELLAZOSTER VIRUS (VZV)) - Google Patents

Vaccine against varicella-zoster virus (VZV) (VACCINES AGAINST VARICELLAZOSTER VIRUS (VZV))

Info

Publication number
KR950704494A
KR950704494A KR1019950702600A KR19950702600A KR950704494A KR 950704494 A KR950704494 A KR 950704494A KR 1019950702600 A KR1019950702600 A KR 1019950702600A KR 19950702600 A KR19950702600 A KR 19950702600A KR 950704494 A KR950704494 A KR 950704494A
Authority
KR
South Korea
Prior art keywords
vzv
iep
protein
physiologically functional
functional derivative
Prior art date
Application number
KR1019950702600A
Other languages
Korean (ko)
Inventor
야코부스 파울
마쌔르 마르크
하우몬트 마셸
볼렌 알렉스
Original Assignee
쟝 슈테펜
스미쓰클라인 비챰 바이올로지칼스(에스.에이.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쟝 슈테펜, 스미쓰클라인 비챰 바이올로지칼스(에스.에이.) filed Critical 쟝 슈테펜
Publication of KR950704494A publication Critical patent/KR950704494A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

본 발명은 수두-대상포진 바이러스의 직접적인 초기 단백질 175(IEP 175) 및 그것의 유도체를 재조합 기법에 의하여 제조하는 방법에 관한 것이다. IEP 175에 대한 구조적으로 또는 기능적으로 상동하는 DNA 및 아미노산 서열, 및 융합 단백질 및 진핵 숙주 세포용 벡터가 제공된다. 상기 단백질 및 그것의 유도체는 VZV에 대한 백신으로서 사용된다.The present invention relates to a method for preparing direct early protein 175 (IEP 175) and derivatives thereof of varicella-zoster virus by recombinant techniques. Structurally or functionally homologous DNA and amino acid sequences to IEP 175 and vectors for fusion proteins and eukaryotic host cells are provided. The protein and derivatives thereof are used as a vaccine against VZV.

Description

수두-대상포진 바이러스(VZV)에 대한 백신(VACCINES AGAINST VARICELLAZOSTER VIRUS(VZV))Vaccine against varicella-zoster virus (VZV) (VACCINES AGAINST VARICELLAZOSTER VIRUS (VZV))

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 VZV IEP 175단백질의 염기서열 및 상응하는 아미노산 서열을 도시한다,Figure 1 shows the nucleotide sequence of the VZV IEP 175 protein and the corresponding amino acid sequence,

제2도는 pNIV2026의 DNA 삽입물의 구조를 도시한다,2 shows the structure of the DNA insert of pNIV2026.

제3도는 재조합 바큘로바이러스의 전달 플라스미드 pNIV2038을 도시한다.3 shows the delivery plasmid pNIV2038 of recombinant baculovirus.

Claims (12)

천연 VZV IEP 175에 기능적으로 동등한 VZV오염물이 없는 VZV IEP 175 및 그것의 생리적으로 기능적인 유도체.VZV IEP 175 and its physiologically functional derivatives free of VZV contaminants functionally equivalent to native VZV IEP 175. 제1항에 있어서, 제1도에 도시된 서열에 실질적으로 상동하는 아미노산을 가지는 것을 특징으로 하는 VZV IEP 175.VZV IEP 175 according to claim 1, having amino acids substantially homologous to the sequence shown in FIG. 제1항에 있어서, 적당한 숙주로부터 발현시 분비가능한 것을 특징으로 하는 VZV IEP 175의 생리적으로 기능적인 유도체.The physiologically functional derivative of VZV IEP 175 according to claim 1, wherein said physiologically functional derivative of VZV IEP 175 is secretable upon expression from a suitable host. 제3항에 있어서, 아미노산 226 내지 257 과 648 내지 733이 결실되어 있는 것을 특징으로 하는 유도체.The derivative according to claim 3, wherein the amino acids 226 to 257 and 648 to 733 are deleted. 융합 |의 일부가 제1항 내지 4항에 따르는 VZV IEP 175 또는 그것의 생리적으로 기능적인 유도체를 포함하는 융합 단백질.A fusion protein, wherein part of the fusion | comprises the VZV IEP 175 or a physiologically functional derivative thereof according to claim 1. 제5항에 있어서, 그것의 일부가 VZV로부터의 유도체인 고정 수단이 없는 gp11단백질을 포함하는 것을 특징으로 하는 융합 단백질.6. The fusion protein of claim 5, wherein a portion of it comprises a gp11 protein without anchor means that is a derivative from VZV. 진핵 숙주 세포에서 기능하는 조절 영역에 작동가능하게 결합된 제1항 내지 6항 중 어느 한 항을 따르는 단백질을 코드화하는 DNA서열을 포함하는 벡터.A vector comprising a DNA sequence encoding a protein according to any one of claims 1 to 6 operably linked to a regulatory region that functions in a eukaryotic host cell. 제7항에 따르는 벡터로 숙주를 형질전환시키고, 그 결과로 생성된 단백질을 회수하는 겻으로 이루어지는, 제1항 내지 6항중 어느 한 항을 따르는 단백질의 제조 방법.A method for producing a protein according to any one of claims 1 to 6, comprising the step of transforming a host with a vector according to claim 7 and recovering the resulting protein. 약제학적으로 허용되는 희석제, 부형제 또는 담체와의 혼합 형태로 제1항 내지 6항중 어느 한 항을 따르는 단백질을 포함하는 백신 조성물.A vaccine composition comprising a protein according to any one of claims 1 to 6 in mixed form with a pharmaceutically acceptable diluent, excipient or carrier. 의학에 사용하기 위한 제1항 내지 6항 중 어느 한 항을 따르는 VZV IEP 175 또는 그것의 생리적으로 기능적인 유도체.VZV IEP 175 or a physiologically functional derivative thereof according to any one of claims 1 to 6 for use in medicine. VZV감염에 민감한 개체를 예방학적으로 치료하기 위한 백신을 제조하기 위하여 제1항 내지 6항중 어느 한 항을 따르는 VZV IEP 175 또는 그것의 생리적으로 기능적인 유도체를 사용하는 방법.Use of the VZV IEP 175 according to any one of claims 1 to 6 or a physiologically functional derivative thereof according to any one of claims 1 to 6 for the preparation of a vaccine for the prophylactic treatment of a subject susceptible to VZV infection. 제1항 내지 6항에 따르는 단백질의 비-독성적 유효량을 혼합하는 것을 포함하는, VZV감염에 민감한 개체를 예방학적으로 치료하는 방법.A method for prophylactically treating a subject susceptible to VZV infection, comprising mixing a non-toxic effective amount of a protein according to claim 1. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950702600A 1992-12-23 1993-12-17 Vaccine against varicella-zoster virus (VZV) (VACCINES AGAINST VARICELLAZOSTER VIRUS (VZV)) KR950704494A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9226768.1 1992-12-23
GB929226768A GB9226768D0 (en) 1992-12-23 1992-12-23 Vaccines
PCT/EP1993/003626 WO1994014962A1 (en) 1992-12-23 1993-12-17 Vaccines against varicella-zoster virus (vzv)

Publications (1)

Publication Number Publication Date
KR950704494A true KR950704494A (en) 1995-11-20

Family

ID=10727070

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950702600A KR950704494A (en) 1992-12-23 1993-12-17 Vaccine against varicella-zoster virus (VZV) (VACCINES AGAINST VARICELLAZOSTER VIRUS (VZV))

Country Status (11)

Country Link
EP (1) EP0675957A1 (en)
JP (1) JPH08504592A (en)
KR (1) KR950704494A (en)
CN (1) CN1095106A (en)
AU (1) AU672870B2 (en)
CA (1) CA2152256A1 (en)
GB (1) GB9226768D0 (en)
MX (1) MX9307998A (en)
NZ (1) NZ259362A (en)
WO (1) WO1994014962A1 (en)
ZA (1) ZA939564B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
CN110343722A (en) * 2019-07-03 2019-10-18 上海大学 A method of varicella virus v-Oka plants of truncated-type glycoprotein E of recombinant expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE119939T1 (en) * 1989-06-27 1995-04-15 Smithkline Beecham Biolog LINKS.
JP3026029B2 (en) * 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 Recombinant varicella virus and its production method

Also Published As

Publication number Publication date
AU672870B2 (en) 1996-10-17
AU5814494A (en) 1994-07-19
EP0675957A1 (en) 1995-10-11
JPH08504592A (en) 1996-05-21
WO1994014962A1 (en) 1994-07-07
NZ259362A (en) 1996-10-28
MX9307998A (en) 1994-08-31
ZA939564B (en) 1994-08-15
GB9226768D0 (en) 1993-02-17
CA2152256A1 (en) 1994-07-07
CN1095106A (en) 1994-11-16

Similar Documents

Publication Publication Date Title
CA2222456A1 (en) Vaccines against hepatitis c
CA2228221A1 (en) Papillomavirus polyprotein constructs
US20020161218A1 (en) Hepatitis C virus vaccine
CA2305683A1 (en) Immunogenic peptides from the hpv e7 protein
Berman et al. Engineering glycoproteins for use as pharmaceuticals
BR9812240A (en) Altered g protein or rsv polypeptide, use of it, nucleic acid molecule encoding an altered g protein or rsv polypeptide, nucleic acid construction, recombinant host cell, processes of producing an altered g protein or rsv polypeptide immunogenic composition , to induce an immune response in a vertebrate, to inhibit the induction of disease increase after vaccination and subsequent infection of a vertebrate with rsv and to immunize a vertebrate against rsv, vaccine composition, vaccine, and, composition immunogenic
KR970705408A (en) Haemophilus adhesion and penetration proteins (HAEMOPHILUS ADHERENCE AND PENETRATION PROTEINS)
KR890700030A (en) Vaccines and diagnostic methods for influenza (Haemophilus influenzae)
KR970703428A (en) FUSION GLYCOPROTEIN FROM HCMV AND HSV FROM HCMV AND HSV
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
KR950704494A (en) Vaccine against varicella-zoster virus (VZV) (VACCINES AGAINST VARICELLAZOSTER VIRUS (VZV))
AR029168A1 (en) A COMPOSITION PEPTIDIC NUCLEIC ACIDS AND A METHOD TO PREPARE IT
EP0257721B1 (en) Vaccine
NZ507983A (en) A polypeptide comprising the amino acid of an n- terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
DE69021886D1 (en) OUTER MEMBRANE PROTEIN P1 AND PEPTIDES FROM HAEMOPHILUS INFLUENZAE TYPE B.
RU95113194A (en) VACCINES, METHOD OF OBTAINING, APPLICATION OF NON-INFECTIOUS SUBVIRUS PARTICLES, VECTORS APPLICATION OF NUCLEIC ACID
CA2067469A1 (en) Recombinant vaccine against marek's disease
WO1992011370A3 (en) Polypeptides derived from proteins of the hepatitis c virus
KR960702000A (en) RECOMBINANT ANTIGENS FROM MUMPS VIRUS AND THEIR USE IN VACCINES
AU6393990A (en) Hiv related peptides
US20080131450A1 (en) Immunogenic complexes, preparation method thereof and use of same in pharmaceutical compositions
CA2402339A1 (en) Viral antigen and vaccine against isav (infectious salmon anaemia virus)
Dietzschold et al. Synthesis of an antigenic determinant of the HSV gD that stimulates the induction of virus-neutralizing antibodies and confers protection against a lethal challenge of HSV.
WO2002010379B1 (en) Modified cea and uses thereof
PT96223A (en) Process for the preparation of a viral agent responsible for post-transfusion non-A non-B hepatitis

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid